endometrioid

en·do·me·tri·oid

(en'dō-mē'trē-oyd),
Microscopically resembling endometrial tissue.

en·do·me·tri·oid

(en'dō-mē'trē-oyd)
Microscopically resembling endometrial tissue.
References in periodicals archive ?
Previous research shows that ARID1A mutations that prevent cellular production of ARID1A are found in about 50% of ovarian clear cell carcinomas, 35% of uterine endometrioid endometrial adenocarcinomas and 30% of ovarian endometrioid carcinomas.
Also, AstraZeneca and MSD are exploring additional trials in ovarian cancer, including the ongoing phase III PAOLA-1 trial, which is testing Lynparza in combination with bevacizumab as a first-line maintenance treatment for women with newly-diagnosed, advanced, stage IIIB-IV high grade serous or endometrioid ovarian cancer, regardless of BRCA status.
AstraZeneca and MSD are exploring additional trials in ovarian cancer, including the ongoing Phase III PAOLA-1 trial, which is testing Lynparza in combination with bevacizumab as a 1st-line maintenance treatment for women with newly-diagnosed, advanced, stage IIIB-IV high grade serous or endometrioid ovarian cancer, regardless of BRCA status.
Adequate paraffin cell blocks for immunohistochemical studies were available for all 113 patients (94 serous carcinomas, 83.2% [93 high grade and 1 low grade]; 5 endometrioid adenocarcinomas [4.4%], 2 mucinous carcinomas [1.8%], 1 undifferentiated carcinoma [0.9%], 1 high grade neuroendocrine carcinoma [0.9%], and 10 carcinomas of unknown type [8.8%]).
Unlike bilateral tubal ligation, which has a greater protective risk of endometrioid and clear-cell carcinoma of the ovary, bilateral salpingectomy appears to further reduce risk of serous carcinoma of the ovaries as well.
It was followed by endometrioid adenocarcinoma 20(13.7%), mucinous cystadenocarcinoma 15(10.3%), granulosa cell tumour 15(10.3%), metastatic tumour 12(8.2%), mixed germ cell tumour 8(5.5%), yolk sac tumour 5(3.4%), mixed surface epithelial tumour 4(2.7%), dysgerminoma 4(2.7%), fibrothecoma 3(2.1%), transitional cell tumour 1(0.7%) and sertoli-stromal cell tumour 1(0.7%).
[3] Endometrioid endometrial carcinoma (EECA) accounts for three fourths of endometrial cancers and are believed to develop following a continuum of premalignant lesions ranging from endometrial hyperplasia without atypia, to endometrial hyperplasia with atypia and finally to well differentiated carcinoma.
([paragraph]) Uterine cancers were classified by histologic type (endometrioid carcinoma, other carcinoma, carcinosarcoma, and sarcoma).